BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15746051)

  • 1. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
    Jahrsdorfer B; Mühlenhoff L; Blackwell SE; Wagner M; Poeck H; Hartmann E; Jox R; Giese T; Emmerich B; Endres S; Weiner GJ; Hartmann G
    Clin Cancer Res; 2005 Feb; 11(4):1490-9. PubMed ID: 15746051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
    Jahrsdörfer B; Wooldridge JE; Blackwell SE; Taylor CM; Griffith TS; Link BK; Weiner GJ
    J Leukoc Biol; 2005 Mar; 77(3):378-87. PubMed ID: 15582984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.
    Jahrsdörfer B; Hartmann G; Racila E; Jackson W; Mühlenhoff L; Meinhardt G; Endres S; Link BK; Krieg AM; Weiner GJ
    J Leukoc Biol; 2001 Jan; 69(1):81-8. PubMed ID: 11200072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
    Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides.
    Henault M; Lee LN; Evans GF; Zuckerman SH
    J Immunol Methods; 2005 May; 300(1-2):93-9. PubMed ID: 15894327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium.
    Pedersen G; Andresen L; Matthiessen MW; Rask-Madsen J; Brynskov J
    Clin Exp Immunol; 2005 Aug; 141(2):298-306. PubMed ID: 15996194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG ODN enhances the efficacy of rituximab in non-Hodgkin lymphoma.
    Buhé V; Guerrier T; Youinou P; Berthou C; Loisel S
    Ann N Y Acad Sci; 2009 Sep; 1173():858-64. PubMed ID: 19758238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
    Mankaï A; Buhé V; Hammadi M; Youinou P; Ghedira I; Berthou C; Bordron A
    Ann N Y Acad Sci; 2009 Sep; 1173():721-8. PubMed ID: 19758221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
    Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
    J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice.
    Brummel R; Roberts TL; Stacey KJ; Lenert P
    Eur J Immunol; 2006 Jul; 36(7):1951-62. PubMed ID: 16791898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.
    Mason KA; Ariga H; Neal R; Valdecanas D; Hunter N; Krieg AM; Whisnant JK; Milas L
    Clin Cancer Res; 2005 Jan; 11(1):361-9. PubMed ID: 15671567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
    Ponzio NM; Cutro S; Hu J; Marzouk A; Marshall JD
    Int Immunopharmacol; 2006 Dec; 6(13-14):2057-68. PubMed ID: 17161362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis.
    Kikuchi K; Lian ZX; Kimura Y; Selmi C; Yang GX; Gordon SC; Invernizzi P; Podda M; Coppel RL; Ansari AA; Ikehara S; Miyakawa H; Gershwin ME
    J Autoimmun; 2005 Jun; 24(4):347-52. PubMed ID: 15878652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma.
    Agrelo R; Setien F; Espada J; Artiga MJ; Rodriguez M; Pérez-Rosado A; Sanchez-Aguilera A; Fraga MF; Piris MA; Esteller M
    J Clin Oncol; 2005 Jun; 23(17):3940-7. PubMed ID: 15867203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional TLR9 modulates bone marrow B cells from rheumatoid arthritis patients.
    Rudnicka W; Burakowski T; Warnawin E; Jastrzebska M; Bik M; Kontny E; Chorazy-Massalska M; Radzikowska A; Buler M; Maldyk P; Maslinski W
    Eur J Immunol; 2009 May; 39(5):1211-20. PubMed ID: 19384869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.